|
US3262977A
(en)
*
|
1962-03-10 |
1966-07-26 |
Chinoin Gyogyszer Es Vegyeszet |
N-aralkyl-1, 1-diphenyl-propylamine derivatives
|
|
NL296693A
(OSRAM)
*
|
1962-08-16 |
|
|
|
|
DK111894A
(OSRAM)
|
1962-11-15 |
|
|
|
|
FR95908E
(fr)
*
|
1963-11-09 |
1972-01-31 |
Degussa |
Procédé de préparation de nouvelles aminocétones et des alcools secondaires correspondants.
|
|
DE1231704B
(de)
|
1963-12-19 |
1967-01-05 |
Josef Klosa Dipl Chem Dr Rer N |
Verfahren zur Herstellung neuer Diaryl-alkylaminoverbindungen mit heterocyclischen Ringen
|
|
US3457354A
(en)
*
|
1965-09-21 |
1969-07-22 |
Merck & Co Inc |
Treatment of hypertension with 2-hydroxy (or amino) - 4,5 - dihydroxyphenethylamine derivatives
|
|
US3895057A
(en)
*
|
1967-10-13 |
1975-07-15 |
Dainippon Pharmaceutical Co |
Aminoalkanols and their pharmaceutically acceptable acid-addition salts, and production thereof
|
|
US4329367A
(en)
*
|
1974-08-05 |
1982-05-11 |
Ciba-Geigy Corporation |
1-(Aralkoxyphenyl)-2-(bis-arylalkylamino)-alkanes
|
|
DE2902172C2
(de)
*
|
1979-01-20 |
1984-05-10 |
UOP Inc., 60016 Des Plaines, Ill. |
Verfahren zur Herstellung eines N,N'-Dialkylphenylendiamins
|
|
ATE33208T1
(de)
*
|
1982-04-23 |
1988-04-15 |
Caola Kozmetikai |
Kosmetische zusammensetzungen enthaltend phenylamin und deren herstellung.
|
|
NZ215753A
(en)
*
|
1985-04-16 |
1989-10-27 |
Hoffmann La Roche |
Phenethanolamine derivatives and pharmaceutical compositions
|
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
|
CA2434436A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Teddy Kosoglou |
Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
|
|
WO2002058685A2
(en)
*
|
2001-01-26 |
2002-08-01 |
Schering Corporation |
Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
|
|
ES2274013T3
(es)
*
|
2001-01-26 |
2007-05-16 |
Schering Corporation |
Combinaciones de activador(es) del receptor activado por el proliferador de los peroxisomas (ppar) e inhibidor(es)m de la absorcion de estelores y tratamientos para trastornos vasculares.
|
|
CA2434430A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Harry R. Davis |
The use of substituted azetidinone compounds for the treatment of sitosterolemia
|
|
BR0206639A
(pt)
*
|
2001-01-26 |
2004-02-25 |
Schering Corp |
Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
|
|
JP2004521894A
(ja)
*
|
2001-01-26 |
2004-07-22 |
シェーリング コーポレイション |
胆汁酸金属イオン封鎖剤およびステロール吸収阻害剤の併用および血管適応症の治療
|
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
|
EP1392287B8
(en)
*
|
2001-05-25 |
2007-01-10 |
Schering Corporation |
Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
|
|
AU2002336609B2
(en)
*
|
2001-09-21 |
2006-08-24 |
Merck Sharp & Dohme Corp. |
Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
|
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
|
DE60229406D1
(de)
*
|
2001-09-21 |
2008-11-27 |
Schering Corp |
Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en)
|
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
|
ATE502635T1
(de)
|
2002-08-19 |
2011-04-15 |
Pfizer |
Kombinationstherapie gegen hyperproliferative erkrankungen
|
|
WO2004043457A1
(en)
*
|
2002-11-06 |
2004-05-27 |
Schering Corporation |
Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
|
|
CN1756756A
(zh)
|
2003-03-07 |
2006-04-05 |
先灵公司 |
取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
|
|
US7235543B2
(en)
|
2003-03-07 |
2007-06-26 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
|
WO2004081004A1
(en)
*
|
2003-03-07 |
2004-09-23 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
|
WO2005046797A2
(en)
*
|
2003-11-05 |
2005-05-26 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
|
CA2574958A1
(en)
*
|
2004-07-26 |
2006-02-09 |
Cotherix, Inc. |
Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
|
|
US20060063803A1
(en)
*
|
2004-09-23 |
2006-03-23 |
Pfizer Inc |
4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
|
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
|
WO2007050783A2
(en)
|
2005-10-26 |
2007-05-03 |
Asahi Kasei Pharma Corporation |
Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
|
|
EP2351569B1
(en)
|
2005-10-26 |
2012-08-22 |
Asahi Kasei Pharma Corporation |
Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
|
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
|
US7919506B2
(en)
|
2006-03-10 |
2011-04-05 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
|
WO2008070496A2
(en)
|
2006-12-01 |
2008-06-12 |
Bristol-Myers Squibb Company |
N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
|
|
ES2393885T7
(es)
|
2007-06-04 |
2014-01-30 |
Synergy Pharmaceuticals Inc. |
Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
WO2009149279A2
(en)
|
2008-06-04 |
2009-12-10 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
AU2009270833B2
(en)
|
2008-07-16 |
2015-02-19 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
US8883844B2
(en)
|
2010-09-24 |
2014-11-11 |
Nitrogenix Inc. |
Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
|
|
US9486494B2
(en)
|
2013-03-15 |
2016-11-08 |
Synergy Pharmaceuticals, Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
WO2014151206A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
JP2016516804A
(ja)
|
2013-04-17 |
2016-06-09 |
ファイザー・インク |
心血管疾患を治療するためのn−ピペリジン−3−イルベンズアミド誘導体
|
|
EP3004138B1
(en)
|
2013-06-05 |
2024-03-13 |
Bausch Health Ireland Limited |
Ultra-pure agonists of guanylate cyclase c, method of making and using same
|
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
|
BR112021013807A2
(pt)
|
2019-01-18 |
2021-11-30 |
Astrazeneca Ab |
Inibidores de pcsk9 e seus métodos de uso
|